What is the Clinical Effectiveness of orphan drugs in COVID-19 patients when compared with Standard Care?
According to World Heath Organisation on 16th August 2021, there have been 207,173,086 confirmed cases of Covid-19, including 4,361,996 deaths, reported to WHO. Where as in India 16th August 2021, there have been 32,225,513 confirmed cases of Covid-19 with 431,642 deaths, reported to WHO.
An Orphan Drug is a Pharmaceutical agent that is used to treat a rare medical condition. Orphan Drugs which are used in Covid-19 like Anakinra, Nitazoxanide, Barcitinib.
Standard Care/Usual Care/Placebo
The primary outcome will be reduction in mortality, we will describe the clinical effectiveness of the orphan drugs in COVID-19 patients tabulated for each study groups (intervention and control). The secondary outcomes to be assed will be the need for intubation, increase in oxygenation, decrease in average length of stay (ALOS).